Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00147654 · ClinicalTrials.gov registry record · Phase 4
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
A Phase 4 study of Urinary Incontinence, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 830
- Enrollment target
- 20
- Study locations
NCT00147654: Completed Phase 4 study of Urinary Incontinence, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00147654 is a Phase 4 study of Urinary Incontinence that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 830 participants, above the 245-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (239% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00147654, a Phase 4 study of Urinary Incontinence, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 830 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge incontinence (UUI), with or without bladder outlet obstruction (BOO).
Conditions Studied
Interventions
- DRUG Tolterodine ER 4 mg QD
- DRUG Tamsulosin 0.4 mg QD
Study Locations (20)
California
- Pfizer Investigational Site - Anaheim
- Pfizer Investigational Site - Culver City
- Pfizer Investigational Site - Fresno
- Pfizer Investigational Site - La Mesa
- Pfizer Investigational Site - Long Beach
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Murrieta
- Pfizer Investigational Site - Poway
- Pfizer Investigational Site - San Bernardino
- Pfizer Investigational Site - Santa Monica
Colorado
- Pfizer Investigational Site - Aurora
- Pfizer Investigational Site - Boulder
- Pfizer Investigational Site - Denver
Alabama
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Homewood
Connecticut
- Pfizer Investigational Site - New Britain
- Pfizer Investigational Site - Waterbury
Florida
- Pfizer Investigational Site - Melbourne
- Pfizer Investigational Site - Ocala
Arizona
- Pfizer Investigational Site - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 830 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
What the finished NCT00147654 record still lists
NCT00147654 is an interventional study that assigns participants to a tested intervention. The registered 830 participants enrollment target is mid-sized for trials with a published cap, above the 245-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (239% higher).
The record links to 1 condition, with Urinary Incontinence appearing as the primary indexed condition, and to 2 interventions - of which Tolterodine ER 4 mg QD is the first listed.
NCT00147654 names 20 study sites across 6 states, led by California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT00147654 about?
NCT00147654 is a clinical study titled "Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction". The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge incontinence (UUI), with or without bladder outlet obstruction (BOO).
What is the current status of trial NCT00147654?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 830 participants. The study started on 2004-11. Estimated completion is 2006-05.
What conditions does trial NCT00147654 study?
This clinical trial studies the following conditions: Urinary Incontinence.
What interventions are being tested in trial NCT00147654?
The interventions under investigation include: Tolterodine ER 4 mg QD (DRUG), Tamsulosin 0.4 mg QD (DRUG).
Who is sponsoring clinical trial NCT00147654?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00147654 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00147654's enrollment target sits among peer trials
830 3rd of 48 higher than 46 of 48 other Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TReating Incontinence for Underlying Mental and Physical Health
RECRUITING · Phase 4
-
A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
COMPLETED · Phase 4
-
NXT Post-Market Clinical Follow-up
RECRUITING
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
-
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- NCT06868277 · 830 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- NCT06910553 · 832 participants
IBD Pregnancy Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia